COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03% Market Closed
Market Cap: 9.4m CAD

COSCIENS Biopharma Inc
Accounts Payable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

COSCIENS Biopharma Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Accounts Payable
$1m
CAGR 3-Years
14%
CAGR 5-Years
28%
CAGR 10-Years
-9%
Theratechnologies Inc
TSX:TH
Accounts Payable
$23.1m
CAGR 3-Years
-19%
CAGR 5-Years
-5%
CAGR 10-Years
13%
Repare Therapeutics Inc
NASDAQ:RPTX
Accounts Payable
$1.3m
CAGR 3-Years
-48%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Accounts Payable
$2.2m
CAGR 3-Years
N/A
CAGR 5-Years
-36%
CAGR 10-Years
-5%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Accounts Payable
$4.6m
CAGR 3-Years
14%
CAGR 5-Years
15%
CAGR 10-Years
19%
Spectral Medical Inc
TSX:EDT
Accounts Payable
CA$3m
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
1%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.08 CAD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's Accounts Payable?
Accounts Payable
1m USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Accounts Payable amounts to 1m USD.

What is COSCIENS Biopharma Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
-9%

Over the last year, the Accounts Payable growth was -57%. The average annual Accounts Payable growth rates for COSCIENS Biopharma Inc have been 14% over the past three years , 28% over the past five years , and -9% over the past ten years .

Back to Top